Literature DB >> 28965278

The value of delaying hCG administration to enable maturation of medium-sized follicles in patients undergoing superovulation for IVF/ICSI.

Awoniyi O Awonuga1, Karen Wheeler2, Mili Thakur2,3, Roohi Jeelani2, Michael P Diamond4, Elizabeth E Puscheck2.   

Abstract

PURPOSE: The purpose of the study is to determine whether continued stimulation of mature follicles to allow "catch up" growth of medium-sized follicles in assisted reproductive technology compromises the clinical pregnancy (CPR) and live birth (LBR) rates in IVF/ICSI cycles.
METHODS: This retrospective cohort study reviewed 200 first IVF ± ICSI cycles out of a total of 340 cycles with complete data. Women underwent stimulation protocols with gonadotropins (Gn) and GnRH antagonist. Treatment cycles were divided into two groups (Gp): hCG administration delayed despite the presence of two mature follicles, defined as ≥ 18 mm [Gp1, n = 79] and hCG administration given when there were two mature follicles [Gp2, n = 121].
RESULTS: The patients in Gp1 were significantly younger than those in Gp2 [32.9 (4.5) vs. 34.3 (4.8), p = 0.04] and needed a median of one more day of superovulation before ovulation was triggered with hCG. The extra days was associated with the use of 450 [75-2025] more Gn, such that at the time the hCG was administered, patient's in group 1 had developed significantly greater number of follicles ≥ 18 mm [mean (SD), 4.9 (1.8) vs. 3.4 (1.7), p < 0.0001]. The clinical pregnancy (48.1 vs. 38.0%, [OR (95% CI)] [1.6 (1.0-2.5), p = 0.09]) and live birth (43.0 vs. 35.5%, [1.4 (0.9-2.3), p = 0.21]) rates per cycle started were not significantly different between the two groups. Forward stepwise logistic regression showed that only maternal age (p = 0.04) influenced clinical pregnancy rates (OR = 0.88, CI 0.78-0.99) and only the number of days for superovulation influenced live birth rates (OR = 0.65, CI 0.486-0.869).
CONCLUSION: This study demonstrated that delaying hCG administration to allow further growth of the medium-sized follicles added further days of superovulation and cost without improvement in CPR and LBR.

Entities:  

Keywords:  Follicles; IVF stimulation; Oocyte retrieval; Superovulation; hCG

Mesh:

Substances:

Year:  2017        PMID: 28965278      PMCID: PMC5845031          DOI: 10.1007/s10815-017-1056-6

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  21 in total

1.  Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes.

Authors:  K P Tremellen; M Lane
Journal:  Hum Reprod       Date:  2010-03-09       Impact factor: 6.918

2.  Utilization of retrieved oocytes as an index of the efficiency of superovulation strategies for in-vitro fertilization treatment.

Authors:  G I Meniru; I L Craft
Journal:  Hum Reprod       Date:  1997-10       Impact factor: 6.918

3.  Timing of human chorionic gonadotrophin (hCG) hormone administration in IVF protocols using GnRH antagonists: a randomized controlled trial.

Authors:  L Morley; T Tang; E Yasmin; R Hamzeh; A J Rutherford; A H Balen
Journal:  Hum Fertil (Camb)       Date:  2012-09       Impact factor: 2.767

4.  Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.

Authors:  C Albano; R E Felberbaum; J Smitz; H Riethmüller-Winzen; J Engel; K Diedrich; P Devroey
Journal:  Hum Reprod       Date:  2000-03       Impact factor: 6.918

5.  Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE.

Authors:  J de Mouzon; V Goossens; S Bhattacharya; J A Castilla; A P Ferraretti; V Korsak; M Kupka; K G Nygren; A Nyboe Andersen
Journal:  Hum Reprod       Date:  2010-06-22       Impact factor: 6.918

6.  Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins.

Authors:  R N Porter; W Smith; I L Craft; N A Abdulwahid; H S Jacobs
Journal:  Lancet       Date:  1984-12-01       Impact factor: 79.321

7.  Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study.

Authors:  R E Felberbaum; C Albano; M Ludwig; H Riethmüller-Winzen; M Grigat; P Devroey; K Diedrich
Journal:  Hum Reprod       Date:  2000-05       Impact factor: 6.918

8.  Programming in vitro fertilization for a 5- or 3-day week.

Authors:  E S Dimitry; S A Bates; T Oskarsson; R Margara; R M Winston
Journal:  Fertil Steril       Date:  1991-05       Impact factor: 7.329

9.  Timed oocyte collection in an assisted conception programme using GnRH analogue.

Authors:  H I Abdalla; R J Baber; T Leonard; A Kirkland; A Mitchell; M Power; E Owen; J W Studd
Journal:  Hum Reprod       Date:  1989-11       Impact factor: 6.918

10.  Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists.

Authors:  Efstratios M Kolibianakis; Carola Albano; Michel Camus; Herman Tournaye; André C Van Steirteghem; Paul Devroey
Journal:  Fertil Steril       Date:  2004-07       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.